Perioperativer Umgang mit modernen oralen Antikoagulanzien in der Herzchirurgie
作者： A. Meyer , J. Kempfert , M. Arsalan , T. Walther
DOI: 10.1007/S00398-014-1120-9
关键词:
摘要: In den letzten Jahren sind neue Wirkstoffe zur oralen Antikoagulation fur verschiedene Indikationen zugelassen worden. Das perioperative Management dieser neuen Medikamente stellt die Herzchirurgie vor eine Herausforderung. Fur besteht v. a. im Rahmen von Notfalleingriffen Problematik der intraoperativen Hamostase und des Monitorings. Detaillierte Kenntnisse verfugbaren Therapieoptionen hierzu unabdingbar. Aktuell fehlen noch weitgehend evidenzbasierte Empfehlungen spezifische Leitlinien.
springer.com
sci-hub.se 参考文章(37)
Catherine J. Lee, Jack E. Ansell, Direct thrombin inhibitors. British Journal of Clinical Pharmacology. ,vol. 72, pp. 581- 592 ,(2011) , 10.1111/J.1365-2125.2011.03916.X
Charlotte Mérie, Lars Køber, Peter Skov Olsen, Charlotte Andersson, Gunnar Gislason, Jan Skov Jensen, Christian Torp-Pedersen, Association of Warfarin Therapy Duration After Bioprosthetic Aortic Valve Replacement With Risk of Mortality, Thromboembolic Complications, and Bleeding JAMA. ,vol. 308, pp. 2118- 2125 ,(2012) , 10.1001/JAMA.2012.54506
Felix Schiele, Joanne van Ryn, Keith Canada, Corey Newsome, Eliud Sepulveda, John Park, Herbert Nar, Tobias Litzenburger, None, A specific antidote for dabigatran: functional and structural characterization. Blood. ,vol. 121, pp. 3554- 3562 ,(2013) , 10.1182/BLOOD-2012-11-468207
Genmin Lu, Francis R DeGuzman, Stanley J Hollenbach, Mark J Karbarz, Keith Abe, Gail Lee, Peng Luan, Athiwat Hutchaleelaha, Mayuko Inagaki, Pamela B Conley, David R Phillips, Uma Sinha, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nature Medicine. ,vol. 19, pp. 446- 451 ,(2013) , 10.1038/NM.3102
BI Eriksson, OE Dahl, N Rosencher, AA Kurth, C Niek van Dijk, SP Frostick, P Kälebo, AV Christiansen, S Hantel, R Hettiarachchi, J Schnee, HR Büller, Re-Model Study Group, None, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis. ,vol. 5, pp. 2178- 2185 ,(2007) , 10.1111/J.1538-7836.2007.02748.X
John W. Eikelboom, Stuart J. Connolly, Martina Brueckmann, Christopher B. Granger, Arie P. Kappetein, Michael J. Mack, Jon Blatchford, Kevin Devenny, Jeffrey Friedman, Kelly Guiver, Ruth Harper, Yasser Khder, Maximilian T. Lobmeyer, Hugo Maas, Jens-Uwe Voigt, Maarten L. Simoons, Frans Van de Werf, Dabigatran versus Warfarin in Patients with Mechanical Heart Valves New England Journal of Medicine. ,vol. 369, pp. 1206- 1214 ,(2013) , 10.1056/NEJMOA1300615
Joel Dunning, Tom Treasure, Michael Versteegh, Samer AM Nashef, None, Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery European Journal of Cardio-Thoracic Surgery. ,vol. 30, pp. 852- 872 ,(2006) , 10.1016/J.EJCTS.2006.09.003
Reinhold Kreutz, Juan Llau, Bo Norrving, Sylvia Haas, Alexander Turpie, Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor Thrombosis and Haemostasis. ,vol. 108, pp. 876- 886 ,(2012) , 10.1160/TH12-03-0209
Fariba Baghaei, Inger Fagerberg Blixter, Kerstin Gustafsson, Lennart Stigendal, Margareta Sten-Linder, Karin Strandberg, Andreas Hillarp, Tomas Lindahl, , Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thrombosis and Haemostasis. ,vol. 105, pp. 371- 378 ,(2010) , 10.1160/TH10-06-0342
Raymond J. Chang, Terence M. Doherty, Steven L. Goldberg, How does warfarin affect the activated coagulation time? American Heart Journal. ,vol. 136, pp. 477- 479 ,(1998) , 10.1016/S0002-8703(98)70223-6